诺唯赞(688105) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥284,980,795.58, a decrease of 5.50% compared to ¥301,571,120.22 in the same period last year[4] - Net profit attributable to shareholders decreased by 63.39% to ¥1,909,911.67 from ¥5,216,369.89 year-on-year[4] - Basic and diluted earnings per share both fell by 50.00% to ¥0.005 from ¥0.01 in the previous year[4] - Total revenue for Q1 2025 was CNY 284,980,795.58, a decrease of 5.2% compared to CNY 301,571,120.22 in Q1 2024[17] - Net profit for Q1 2025 was CNY 1,856,553.27, compared to CNY 4,875,266.29 in Q1 2024, indicating a decline in profitability[18] - The total comprehensive income attributable to the parent company was CNY 3,518,626.02, down from CNY 4,977,050.35 in the previous year, representing a decrease of approximately 29.3%[19] - The company's revenue for Q1 2025 was ¥226,819,281.26, a decrease of 6.5% compared to ¥243,334,887.78 in Q1 2024[25] - Operating profit for Q1 2025 was ¥11,221,646.94, an increase of 7.7% from ¥10,420,588.13 in Q1 2024[26] - Net profit for Q1 2025 reached ¥14,170,607.93, up 2.9% from ¥13,771,348.09 in Q1 2024[26] Research and Development - Research and development expenses totaled ¥66,468,634.05, accounting for 23.32% of operating revenue, a slight decrease of 0.14 percentage points from the previous year[5] - The company reported a decrease in R&D expenses to CNY 66,468,634.05 in Q1 2025 from CNY 70,762,810.52 in Q1 2024, reflecting a focus on cost management[18] - Research and development expenses for Q1 2025 were ¥39,446,368.24, a decrease of 15.6% compared to ¥46,711,723.79 in Q1 2024[26] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥55,017,260.08, an improvement from -¥81,496,867.29 in the previous year[4] - The company's cash and cash equivalents increased to CNY 475,664,910.64 as of March 31, 2025, up from CNY 434,245,326.54 at the end of 2024[13] - The company's cash and cash equivalents at the end of Q1 2025 were CNY 295,911,908.80, down from CNY 908,855,353.96 at the end of Q1 2024[21] - The company reported a net cash flow from operating activities of -¥112,451,869.82 in Q1 2025, an improvement from -¥213,556,683.45 in Q1 2024[29] - The company achieved cash inflow from operating activities totaling ¥1,317,875,880.11 in Q1 2025, significantly higher than ¥199,112,075.59 in Q1 2024[29] - The company reported a decrease in cash flow from financing activities, with a net cash flow of CNY 298,778,467.60 in Q1 2025, compared to negative CNY 334,738,672.19 in Q1 2024[21] Assets and Liabilities - Total assets increased by 4.31% to ¥5,266,304,774.25 compared to ¥5,048,663,079.32 at the end of the previous year[5] - Total assets reached CNY 5,266,304,774.25 as of March 31, 2025, an increase from CNY 5,048,663,079.32 at the end of 2024[14] - Total liabilities increased to CNY 1,365,454,324.70 as of March 31, 2025, compared to CNY 1,105,054,200.00 at the end of 2024[15] - The company's long-term assets decreased to CNY 1,403,369,783.38 as of March 31, 2025, down from CNY 1,477,191,932.56 at the end of 2024[14] - The company's total equity decreased to CNY 3,900,850,449.55 as of March 31, 2025, from CNY 3,943,608,879.32 at the end of 2024[15] - The total current assets amounted to CNY 4,597,540,249.41, an increase from CNY 4,233,836,352.31 in the previous year[23] Investments and Acquisitions - The company acquired a 6.99% stake in Jiangsu Liquid Logic Biotechnology Co., Ltd., bringing its total ownership to 98.42%[10] - The company invested ¥5 million to subscribe for a 0.7825% stake in Suzhou Huiliao Biomedical Technology Co., Ltd.[10] - The company also invested ¥5 million to acquire a 1.6393% stake in Nanjing Lingxin Biotechnology Co., Ltd.[10] - The establishment of a subsidiary, Nanjing Liquid Droplet Biotechnology Co., Ltd., was completed with a registered capital of $7 million, fully owned by LOGILET(UK)[10] Financial Ratios - Basic and diluted earnings per share for Q1 2025 were both ¥0.04, an increase from ¥0.03 in Q1 2024[26]